---
title: "Year-Long Anti-Corruption Drive in China's Pharmaceutical Industry"
description: "Year-Long Anti-Corruption Drive in China's Pharmaceutical Industry"
image: https://image.informedainews.com/2024/09/Soc-3l7-1725272785-0.jpg
---


:::info

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons.  [Find out more >>](/)

:::

# Year-Long Anti-Corruption Drive in China's Pharmaceutical Industry

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">
<img
  src="https://image.informedainews.com/2024/09/Soc-3l7-1725272785-0.jpg"
  alt="Year-Long Anti-Corruption Drive in China's Pharmaceutical Industry"
/>



In the past year, over 30 pharmaceutical executives in China have faced investigation for corruption. The crackdown, initiated by the National Health Commission and nine other departments, has targeted both public and private sectors. Key figures from major companies like Guangzhou Pharmaceutical Group, Shanghai Pharmaceuticals, and China National Pharmaceutical Group have been implicated.

The investigations reveal a pattern of misconduct, including bribery and embezzlement, often linked to high sales expenses and improper practices in academic promotions. Notable cases include the former chairman of Guangzhou Pharmaceutical Group, Li Chuyan, and the ex-chairman of Shanghai Pharmaceuticals, Zhou Jun, both accused of serious violations.

Additionally, several healthcare company CEOs have been detained under suspicion of corruption or other illegal activities. These include Zhou Wei, the chairman of Weining Health, and Su Qingcan, the head of Huaxia Eye Hospital Group.

This widespread scrutiny underscores a significant shift in China's approach to corporate governance and ethical standards within the pharmaceutical industry. The focus on top executives suggests a move towards greater accountability and transparency.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 7    | Comprehensive reporting with balanced viewpoints and in-depth analysis.    |
	| Social Impact | 6     | Extensive discussion, major impact on public opinion and industry practices.    |
	| Credibility    | 6    | Verified by multiple sources, solid evidence from authoritative bodies.    |
	| Potential    | 5    | High potential to influence future governance and ethical standards.    |
	| Practicality    | 5    | Practical, directly applicable to real-world anti-corruption efforts.    |
	| Entertainment Value    | 2    | Limited entertainment value, primarily informative.    |
</TabItem>
</Tabs>

[Full article>>](https://www.thepaper.cn/newsDetail_forward_28596509)
